Lapozan

Olanzapine, the active ingredient in Lapozan, is an atypical antipsychotic presented as an oral tablet for oral use. It is indicated for the management of schizophrenia and bipolar disorder in adult patients, helping to reduce psychotic symptoms, mood swings, and relapse risk.

GNH USA supplies Lapozan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics, ensuring timely delivery across Europe, Asia and the Americas while adhering to stringent Good Distribution Practice standards.

Olanzapine acts on dopaminergic and serotonergic pathways to treat major psychiatric disorders.

- Schizophrenia: reduces positive and negative symptoms, improves thought processes, helps prevent relapse in adult patients, and improves overall functioning. - Bipolar disorder (Manic episodes): stabilizes mood, controls acute mania, reduces the frequency of mood swings, and supports patient stability. - Maintenance therapy for schizophrenia: maintains symptom control over the long term, lowers the risk of hospitalization, and supports daily living activities. - Schizoaffective disorder: alleviates psychotic symptoms and mood disturbances, contributing to improved patient stability.

Olanzapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Weight gain - Drowsiness or sedation - Dry mouth - Constipation

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Severe hyperglycemia or new‑onset diabetes - Agranulocytosis

Before prescribing Olanzapine, clinicians should consider several precautionary measures to ensure patient safety.

- Monitor metabolic parameters: regularly check weight, fasting glucose and lipid profile. - Assess for cardiovascular risk: evaluate blood pressure and heart rate, especially in patients with orthostatic tendencies. - Evaluate hepatic function: adjust use in patients with liver impairment. - Review psychiatric history: avoid use in patients with a history of severe depression or suicidal ideation without close supervision. - Caution in elderly: increased sensitivity to sedation and anticholinergic effects. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Olanzapine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): may increase olanzapine plasma levels, raising toxicity risk. - CNS depressants (e.g., benzodiazepines, opioids): can enhance sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce olanzapine concentrations, diminishing therapeutic effect. - Anticholinergic agents (e.g., diphenhydramine): may worsen anticholinergic side effects. - Antidiabetic drugs: olanzapine may affect glucose control, requiring dose adjustments.